Niagen Bioscience to Present at the Sixth Annual Longevity Summit Taking Place at the Buck Institute for Research on Aging
Niagen Bioscience Expands HSA/FSA Payment Option for the Pharmaceutical-Grade Niagen™ At-Home Injection Kit through Niagen™ Plus
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
Freedom Broker Maintains Buy on Niagen Bioscience, Lowers Price Target to $6
Canaccord Genuity Maintains Buy on Niagen Bioscience, Lowers Price Target to $7
Niagen (NAGE) Q3 2026 Earnings Call Transcript
Niagen Bioscience Inc Q3 2026 Earnings Call Summary
Niagen Bioscience Inc (NAGE) Q3 2026 Earnings Call Highlights: Cash Flow Positive Despite Sales ...
Niagen Bioscience, Inc. (NAGE) Q3 2026 Earnings Call Transcript
Niagen Bioscience (NASDAQ:NAGE) Q3 Revenue Miss Weighs on Shares Despite Positive EBITDA
Niagen Bioscience: Q3 Earnings Snapshot
Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results
Niagen Bioscience Q3 2026 Earnings Call Transcript
Niagen Bioscience Raises FY2026 Sales Guidance from $138.982M-$145.299M to $145.299M-$151.616M vs $130.410M Est
Niagen Bioscience Q3 EPS $(0.01) Misses $0.02 Estimate, Sales $27.192M Miss $32.062M Estimate
Canaccord Genuity Maintains Buy on Niagen Bioscience, Lowers Price Target to $9
Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline
Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion
Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product
Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.